Digital Chain-of-Custody Systems for Cell-Processing Facilities

Abstract

Digital chain-of-custody (CoC) systems are transforming quality assurance and regulatory compliance within cell-processing facilities. Given the complexity, high value, and patient-specific nature of cellular therapeutics, robust digital CoC platforms enable traceability, accountability, and error minimization throughout the entire workflow. This article critically examines the clinical, operational, and regulatory imperatives for deploying digital CoC in cell-processing, explores the epidemiology of errors and risks in current workflows, and synthesizes recent advances, implementation challenges, and guideline recommendations for optimal clinical integration.

Introduction

Cell-processing facilities are at the core of advanced therapies such as autologous and allogeneic stem cell transplants, chimeric antigen receptor (CAR) T-cell therapies, and other regenerative interventions. The highly individualized nature of these treatments mandates rigorous process oversight to ensure that each cellular product administered to a patient is correctly matched, manipulated, and delivered. Digital chain-of-custody systems have emerged as critical infrastructure, replacing paper-based records and manual checkpoints with automated, tamper-evident, and traceable digital workflows. This review discusses the clinical relevance, technology underpinnings, and practical implications of digital CoC adoption in contemporary cell-processing environments.

Epidemiology / Disease Burden

Errors in cell-processing, labeling, and custody though rare can result in catastrophic adverse outcomes including misadministration, graft rejection, or transmission of infectious agents. The global expansion of cell-based therapies, with an estimated 60,000+ hematopoietic stem cell transplants performed annually and rapidly growing numbers of CAR-T infusions, has heightened the need for robust traceability. Reports from transplant registries and adverse event databases highlight that chain-of-custody lapses are responsible for a significant proportion of preventable errors, with the World Marrow Donor Association emphasizing the need for digital traceability to reduce morbidity and mortality.

Pathophysiology

The pathophysiological consequences of chain-of-custody failures in cell-processing arise from three main mechanisms: (1) administration of incorrect or contaminated cellular products, (2) loss of product identity leading to regulatory breaches and patient harm, and (3) delays in therapy due to process bottlenecks or investigations. Even minor lapses can compromise patient safety, trigger immunologic complications, and undermine the efficacy of cellular therapies. Digital CoC systems mitigate these risks by ensuring that every handoff, manipulation, and transport event is digitally recorded, timestamped, and validated against predefined criteria.

Risk Factors

Risk factors for custody errors include high sample throughput, complex multi-step processing protocols, manual data entry, lack of standardization, and inadequate training. Facilities with fragmented or hybrid paper-digital workflows are particularly vulnerable. Human factors such as fatigue, shift changes, and communication breakdowns are compounded by regulatory pressures and the need for rapid turnaround in urgent cases. Digital CoC platforms address these risks by automating checkpoints, enforcing procedural adherence, and providing real-time alerts for deviations.

Clinical Features

From a clinical perspective, chain-of-custody failures may present as unexpected graft failures, adverse reactions, or regulatory non-compliance events. Presentation can be insidious, with identity errors sometimes discovered only during post-infusion audits or registry reconciliation. Digital CoC systems, by providing continuous audit trails and automated error detection, facilitate early identification of discrepancies, enabling prompt corrective actions and improved patient outcomes.

Diagnosis

Diagnosing chain-of-custody lapses traditionally relies on retrospective audits, manual reconciliation of records, and root-cause analysis following adverse events. Digital CoC systems revolutionize this paradigm by enabling real-time anomaly detection, automated cross-checks, and rapid generation of custody reports. Their integration with laboratory information management systems (LIMS) and electronic health records (EHR) further streamlines diagnosis, ensuring that every product is traceable from collection to infusion.

Treatment & Management

Management of custody-related incidents involves immediate containment of affected products, notification of regulatory bodies, patient re-evaluation, and, where applicable, re-collection or re-processing. Digital CoC platforms expedite root-cause analysis by providing immutable logs of each custody event, reducing investigation times and improving transparency. Proactive management includes regular staff training, simulation of custody breaches, and continuous system validation.

Recent Advances / Emerging Therapies

Recent innovations in digital CoC include blockchain-enabled ledgers, biometric authentication, and integration of Internet-of-Things (IoT) sensors for environmental monitoring during transport and storage. Artificial intelligence algorithms are being developed to predict and prevent process deviations, while cloud-based platforms enhance scalability and interoperability across multi-site facilities. Emerging regulatory frameworks increasingly require or recommend digital traceability as a condition for product licensure and reimbursement.

Guideline Recommendations

International bodies such as the Foundation for the Accreditation of Cellular Therapy (FACT), the International Society for Cell & Gene Therapy (ISCT), and the U.S. Food and Drug Administration (FDA) endorse the use of digital chain-of-custody systems to ensure product identity, integrity, and patient safety. Guidelines emphasize risk-based validation, data security, user access controls, and continuous monitoring. Facilities are advised to maintain dual digital and manual backup systems during transition periods, and to conduct regular audits to ensure compliance with evolving standards.

Conclusion

Digital chain-of-custody systems represent a paradigm shift in the safe, efficient, and regulatory-compliant delivery of cellular therapies. By automating and securing the custody process, these platforms significantly reduce the risk of errors, enhance clinical outcomes, and support the expanding landscape of advanced cell-based interventions. Ongoing innovations and harmonized guidelines will further cement their role as indispensable infrastructure for modern cell-processing facilities, ultimately translating into improved patient safety and therapeutic success.